Wound Management Technologies, Inc Announces Conference Plans and Presentations on...

Wound Management Technologies, Inc Announces Conference Plans and
Presentations on Advanced Wound Care Product

FORT WORTH, Texas, July 7 /PRNewswire/ -- Wound Care Innovations, LLC, a
subsidiary of Wound Management Technologies, Inc., (WNDM.ob), announced today
that it will exhibit at the New Cardiovascular Horizons and Management of the
Diabetic Foot & Wound Healing (NCVH) conference in New OrleansJuly 9-11.

NCVH has become the largest multidisciplinary conference in the country,
bringing together cardiologists, surgeons, podiatrists, wound care
specialists, family practice physicians, diabetologists, and many other
clinicians and specialists who are involved in all aspects of limb salvage,
podiatric wound care, and peripheral vascular treatment. There are over 1,000
expected attendees and one of the most distinguished faculty lists in the
industry.

Two peer reviewed abstracts being presented at the conference featuring Wound
Care Innovations' advanced wound care collagen product, CellerateRx(R). One
of the abstracts is entitled "Emerging Use of Topical Biologics in Limb
Salvage: The Role of 'Activated Collagen' in the multimodality Treatment"
presented by Gary M. Rothenberg, DPM, Director of Resident Training-Attending
Podiatrist, Miami VA Healthcare System. Dr. Rothenberg is also one of the
featured speakers and will be presenting "Prophylactic Surgery in the Diabetic
Foot and Partial Ray Amputation Outcomes."

Also being presented is "CellerateRx(R) An Evidence Based Skin Tear Study:
Interim Evaluation" by Dr. Jane Fore, MD, FAPWCA, FACCWS, Medical Director,
Tri-State Wound Care and Hyperbaric Center. In addition, Dr. Fore will be
conducting a series of workshops on "The Benefits of Collagen in Wound
Healing: Methods of Action and Selection of Collagen Containing Dressings."

"I am delighted to be conducting the workshop on collagen dressings," states
Dr. Fore. "I have been using CellerateRx(R) in my wound care protocols for
over 5 years now and it is an essential part of my wound care treatments for
success. I am excited to be able to show practitioners the many ways
CellerateRx(R) can be used in their wound care practice, especially with
difficult or challenging wounds such as diabetic ulcers."

"We are particularly excited about exhibiting at the NCVH conference this
year," states Cathy Bradshaw, President of Wound Care Innovations. "It allows
us to be with the industry leaders and promote our advanced wound care
product, CellerateRx(R). In addition, the two abstracts and workshop provides
an excellent opportunity to highlight the many unique features and
characteristics of CellerateRx(R), particularly in diabetic wound care.
Diabetic ulcers are one of the largest challenges in the health care industry
today, both for the patient and economic expenditures. Statistics show that
around 85% of Lower Extremity Amputation's begin with an ulcer; therefore a
product that manages these wounds more effectively can save limbs and
resources. We are especially seeing great results with the use of
CellerateRx(R) on diabetic ulcers and data continues to support this. We
fully expect that these results will help us to increase our market share in
the U.S. and generate sales internationally."

About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTCBB:WNDM), with its corporate
headquarters in Fort Worth, Texas, markets and distributes wound care products
to the healthcare market under patented technology licensed to the Company.
The Company is positioned and seeks to be a leading provider of wound care
products. For more information on the Company please visit the Company's
Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of
1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080

SOURCE Wound Management Technologies, Inc.

Product Information: Cathy Bradshaw, President, +1-954-315-9242, or
Shareholder Relations, Lucy Singleton, Secretary, +1-817-820-7080